A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MESOS
- Sponsors AstraZeneca
- 14 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 17 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.